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Abstract
Background
To limit the spread of SARS-CoV-2, an evidence-based understanding of the symptoms is
critical to inform guidelines for quarantining and testing. The most common features are pur-
ported to be fever and a new persistent cough, although the global prevalence of these
symptoms remains unclear. The aim of this systematic review is to determine the preva-
lence of symptoms associated with COVID-19 worldwide.
Methods
We searched PubMed, Embase, CINAHL, AMED, medRxiv and bioRxiv on 5th April 2020
for studies of adults (>16 years) with laboratory test confirmed COVID-19. No language or
publication status restrictions were applied. Data were independently extracted by two
review authors into standardised forms. All datapoints were independently checked by three
other review authors. A random-effects model for pooling of binomial data was applied to
estimate the prevalence of symptoms, subgrouping estimates by country. I2 was used to
assess inter-study heterogeneity.
Results
Of 851 unique citations, 148 articles were included which comprised 24,410 adults with con-
firmed COVID-19 from 9 countries. The most prevalent symptoms were fever (78% [95% CI
75%-81%]; 138 studies, 21,701 patients; I2 94%), a cough (57% [95% CI 54%-60%]; 138 stud-
ies, 21,682 patients; I2 94%) and fatigue (31% [95% CI 27%-35%]; 78 studies, 13,385 patients;
I2 95%). Overall, 19% of hospitalised patients required non-invasive ventilation (44 studies,
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6,513 patients), 17% required intensive care (33 studies, 7504 patients), 9% required invasive
ventilation (45 studies, 6933 patients) and 2% required extra-corporeal membrane oxygenation
(12 studies, 1,486 patients). The mortality rate was 7% (73 studies, 10,402 patients).
Conclusions
We confirm that fever and cough are the most prevalent symptoms of adults infected by
SARS-CoV-2. However, there is a large proportion of infected adults which symptoms-
alone do not identify.
Introduction
The novel coronavirus (SARS-CoV-2; 2019-nCoV; COVID-19) pandemic is a global crisis. As
of April 10th 2020, there were over 1.5 million confirmed cases of whom over 92,000 have died
[1]. In the absence of a vaccine or treatment with proven efficacy, limiting human-to-human
transmission is critical [2–4]. Self-isolation (or self-quarantine) is an effective global strategy
for limiting transmission following the emergence of symptoms [5] and equally, the manifesta-
tion of symptoms is used to guide testing.
Coronavirus is most infectious in the early phase of the illness [6,7] [8], so screening people
with compatible symptoms [9] is fundamental to determining who should be quarantined and
be tested [9]. Several systematic reviews have considered the symptoms of COVID-19
(amongst other parameters) [8,10–14] although all of them have major limitations. None sys-
temically searched the grey literature (e.g. preprint archives such as medRxiv and bioRxiv) and
in the context of a pandemic, the quality and quantity of the literature is evolving at speed [15].
Without incorporating all relevant preprints the findings of any systemic review will be weeks-
months out-of-date at the time of publication [16]. Furthermore, with few included studies (30
in the largest and most recent [12]), the range of symptoms were limited and the estimates of
prevalence are likely to be upwardly biased because only unwell patients (largely those admit-
ted to hospital) were tested in the early phase of the outbreak.
To facilitate the rapid dissemination of high-quality open-science, there has been a surge of
preprints related to COVID-19 manuscripts uploaded to the online archives medRxiv and
bioRxiv [15]. The necessity to address deficiencies in current literature and potential to sub-
stantially improve the precision of estimates of symptom prevalence using both indexed and
(the more voluminous and up-to-date) preprint literature from multiple geographical regions,
represents the rational for this review.
The aim of this systematic review is to determine the prevalence of symptoms associated
with COVID-19 worldwide.
Methods
This systematic review was designed and conducted in accordance with the Cochrane Hand-
book of Systematic Reviews [17] and a pre-published protocol [18], and is reported in line
with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
Statement (see S1 Checklist) [18,19].
Participants and studies
Studies reporting the prevalence of patient-reported symptoms or clinician observed features
in adults (>16 years) with laboratory confirmed novel coronavirus (SARS-CoV-2; covid-19)
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derived from oro- or naso-pharyngeal swabs. We excluded case reports, articles which failed to
disaggregate symptoms in adult and paediatric cohorts, studies of patients with prior respira-
tory infections (e.g. tuberculosis) or co-infections with other viruses (e.g. similar viruses
SARS-CoV-1 or HCoV-EMC/2012, etc) and articles which we are unable to translate to
English in a timely fashion.
Target condition
The incubation period of COVID-19 is typically 5 days, but reported to last a maximum of 7
days [20–24]. The illness typically lasts 8 days [21]. Therefore, we will include any symptom(s)
described up to 15 days before laboratory confirmed infection and during the illness.
Search strategy
PubMed, Embase, AMED and CINAHL, medRxiv [25] and bioRxiv were interrogated accord-
ing to our search strategy (S1 Appendix). Searches were limited to 1st January onwards. No
language restrictions were applied.
Study selection process
After de-duplication, all unique citations were independently screened by three review authors
(MG, LG and RGW). The full texts of all potentially relevant articles were obtained. The refer-
ence lists for included articles and other systematic reviews were also scrutinised. Final lists of
included articles were compared and disagreements resolved by consensus discussion between
five authors (MG, LG, ZK, ELC and RGW).
Data extraction
Two authors (MG and LG) independently extracted data and three authors (ZM, ELC and
RGW) checked the accuracy of the extracted data using a standardised spreadsheet. Disagree-
ments were resolved by discussion. We combined the following symptoms: “chest tightness”
into the more prevalent symptom of wheeze; “shivers” and “chills” into rigors; malaise and
“generalised weakness” (in the absence of any objective neurological deficit) into the more
widely reported symptom of fatigue; conjunctivitis, conjunctival congestion and conjunctivital
secretions into conjunctivitis. Where studies reported one symptom “or” another (e.g. nausea
or vomiting) we did not extract this information as it was impossible to disaggregate. Where
studies reported one symptom “and” another (e.g. nausea and vomiting) we extracted the
prevalence of both. When studies grouped symptoms together (e.g. “respiratory symptoms”)
without further description or definition we were not able to extract this information.
Methodological quality assessment
The risk of bias for included studies was not assessed for two main reasons: firstly, there is no
consensus on ideal tool, nor one designed specifically for studies of prevelance [26] and sec-
ondly, such assessments would not change the approach to the modelling or presentation of
the data, as per our protocol. Given such assessments are also time-intensive, we have taken
the pragmatic decision to not perform risk of bias assessments.
Analysis
The pooled prevalence of symptoms were estimated using the metaprop package [27] in Stata/
MP v15. Dersimonian and Laird random-effects were used given the geographical and study-
level heterogeneity. A random-effects model including Freeman-Tukey arcsine transformation
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of the prevalence was used to normalise variance. 95% confidence intervals (CIs) were com-
puted around the study-specific and pooled prevalence based on the score-test statistic. [28].
The variation in prevalence by country was assessed by subgroup meta-analyses and meta-
regression. Statistical heterogeneity is assessed by I2 which corresponds with the proportion of
total variation due to inter-study heterogeneity and by p-values for inter-study heterogeneity
within countries, between countries and overall [29]. Given the use of a random-effects model,
inter-study heterogeneity within countries was only assessable when at least three studies were
available. A z-test (and the corresponding p-values) assessed whether the observed prevalence
was different from zero percent. Publication bias was not assessed.
Results
Study selection
Our search returned 2403 hits in PubMed, 2234 in Embase, 310 in CINAHL, 1 in AMED, and
434 preprints in medRxiv and bioRxiv on 5th April 2020. Following deduplication, the titles and
abstracts of 851 unique records were assessed against the inclusion criteria. 743 of these were
deemed to be potentially eligble. Full text screening then resulted in 148 included articles (Fig 1).
Study characteristics
This review describes 24,410 adults with laboratory confirmed COVID-19 from 9 countries,
including China [30,31,32,33,34,35,36,37,38,39,40,41,42,43,44–49,50–59,60–69,70–79,80–
89,90–99,100–109,110–119,120–129,130–139,140–149,150–159,160–165], the UK [166,167],
the USA [168,169], Singapore [170,171], Italy [172,173], Australia [174], Japan [175], Korea
[176] and the Netherlands [177]. The mean age of patients was 49 years (SD 11) and where sex
data were available, the ratio of males:females was 1.2:1 (10,306:8593). The characteristics of
the included studies are shown in S1 Table.
Thirty-four studies reported that 845 of 7519 patients required non-invasive ventilation
(pooled prevalence 17% [95% CI 11%-24%]; I2 98%). Forty-four studies (6513 patients)
reported that 970 patients were admitted to an intensive care unit (pooled prevalence 19%
[95% CI 13%-26%]; I2 97%). Forty-five studies (6933 patients) reported that 495 required inva-
sive mechanical ventilation (pooled prevalence 9% [95% CI 6%-13%]; I2 95%). Twelve studies
(1486 patients) reported that 2% of patients (36) required extra-corporeal membrane oxygen-
ation (95% CI 0%-5%; I2 95%). Of the 73 studies that reported survival in 10,402 patients, there
were 938 deaths (pooled prevalence 7% [95% CI 4%-11%]; I2 98%) which were attributable to
COVID-19.
Evidence synthesis
Table 1 shows the meta-analysed prevalence of symptoms, group by bodily system, and S2
Table shows the meta-analytical prevalence estimates from studies grouped by geographical
region. The most prevalent symptom in patients with laboratory confirmed COVID-19 was a
fever, experienced by 78% of patients (99% CI 75%-81%; Fig 2 and S2–S5 Figs). Whilst, there
was substantial heterogeneity between countries (I2 94%) with estimates ranging from 83% in
Singapore (99% CI 61%-98%) to 32% in Korea (99% CI 15%-51%), there was no evidence of a
statistically significant difference between countries (S2 Table). A cough was the second most
prevalent symptom, reported by 57% of test-positive patients (95% CI 54%-60%; Fig 3 and S6–
S10 Figs). Whilst there was substantial heterogeneity between countries (I2 94%) with esti-
mates ranging from 18% in Korea (99% CI 8%-36%) to 76% in the Netherlands (95% CI 66%-
83%), there was no evidence of a statistically significant difference.
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Fig 1. Study flow chart.
https://doi.org/10.1371/journal.pone.0234765.g001
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Discussion
This review describes 24,410 adults with laboratory test confirmed COVID-19 from 9 coun-
tries. We confirm that the purported cardinal symptoms of fever and a new persistent cough
are indeed the most prevalent symptoms of COVID-19 worldwide. However, we also show
that at approximately 1 in 5 test-positive adults were never febrile and fewer than 3 in 5 devel-
oped a cough. Since the patients in the included studies are likely to have moderate-severe dis-
ease warranting hospitalisation and thus testing, it is likely that we over-estimate the true
prevalence of symptoms in the population. Consequently, the use of symptoms alone to
screening adults for SARS-CoV-2 infection is likely to miss a substantial number of infected
individuals.
Our point estimates of the prevalence of fever (78%) and cough (57%) are approximately
10% lower than the estimates from prior reviews [8,10–13] which we feel might explained by
two specific factors. Firstly, prior reviews [8,10–13] did not systematically search (or search at
all [8,10,11,13]) for preprints uploaded to online repositories such as medRxiv or bioRxiv [15],
both of which have seen a surge in uploads related to the COVID-19 pandemic [15]. This
Table 1. Meta-analysis of the prevalence of symptoms in adults with laboratory test confirmed COVID-19.
System Symptom Number of studies Number of people Prevalence (95% CI) I2
Systemic Fever 138 21,701 78 (75, 81) 94%
Fatigue 78 13,385 31 (27, 35) 95%
Myalgia 72 11,389 17 (14, 19) 88%
Rigors 17 2834 18 (13, 22) 88%
Arthralgia 2 401 11 (8, 14) /
Rash 1 1099 0 (0, 1) /
Respiratory Any cough (dry or productive) 138 21,682 57 (54, 60) 94%
Dry (non-productive) cough 136 17,380 58 (54, 61) 93%
Productive cough 70 10,017 25 (22, 28) 90%
Dyspnoea 94 12,713 23 (19, 28) 97%
Chest pain 30 3510 7, (4, 10) 92%
Haemoptysis 21 4698 2 (1, 2) 42%
Wheeze 16 2013 17 (9, 26) 96%
Ear, nose and throat Sore throat 78 11,721 12 (10, 14) 88%
Rhinorrhoea 36 10,656 8 (5, 12) 97%
Vertigo / dizziness 16 1972 11 (6, 16) 90%
Nasal congestion 10 2584 5 (3, 7) 78%
Hyposmia 3 317 25 (4, 55) /
Hypogeusia 2 220 4 (1, 8) /
Otalgia 1 68 4 (1, 11) /
Gastrointestinal Diarrhoea 93 11,707 10 (8, 12) 93%
Nausea 27 4584 6 (3, 10) 95%
Vomiting 26 4959 4 (2, 8) 94%
Abdominal pain 19 3331 4 (2, 7) 88%
Central nervous system Headache 65 15,958 13 (10, 16) 97%
Confusion 6 869 11 (7, 15) 67%
Ataxia 1 214 0 (0, 2) /
Eyes Conjunctivitis 9 2715 2 (1, 4) 80%
Ophthalmalgia 1 534 4 (3, 6) /
Photophobia 1 534 3 (2, 4) /
https://doi.org/10.1371/journal.pone.0234765.t001
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explains why the largest and most recent other review (posted on March 25th 2020 in medRxiv
[12]) included just 30 studies. Secondly, several weeks have passed since the other reviews
[8,10–13] were performed and the delay from searching to posting a preprint in medRxiv was
between 11 days [11] and 5 weeks [12,13,178]. For those articles not uploading a preprint, the
delay from searching to publication was 3 weeks [10]. Therefore, it is likely that the prior
reviews [8,10–13] had a higher proportion of adults with more severe disease (given that test-
ing was limited to those admitted to hospital in the early phase of the outbreak) whereas more
recent studies are likely to include adults with mild symptoms due to the wider availability of
testing alongside natural progression of the disease. Conversely, more-recent studies of real-
time population-wide tracking of self-reported symptoms in subsequently test-positive
patients are essentially identical to our point estimates for cough [179]; however, data
Fig 2. Forest plot of the prevalence of fever in adults with laboratory test confirmed COVID-19. The diamonds are
summary estimates from each country.
https://doi.org/10.1371/journal.pone.0234765.g002
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concerning fever [180] are less concordant but given the variability of core body temperature,
methods of measurement and the definition of this symptom, variability is expected.
Limitations
We acknowledge that there is both within-country and between-country differences in the
estimated prevalence of different symptoms, which presents issues with regards to generalising
the findings. However, the unique strength of a meta-analysis is the ability to compare datasets
from difference sources, identify patterns and discrepancies [181], and no statistical technique
is able to correct for weaknesses or idiosyncrasies of the original data. Differences in the study
Fig 3. Forest plot of the prevalence of cough (dry or productive) in adults with laboratory test confirmed COVID-19. The diamonds
are summary estimates from each country.
https://doi.org/10.1371/journal.pone.0234765.g003
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designs, settings and what types of patients (mild, moderate or critically unwell) were sampled
are all likely to be responsible for the observed heterogeneity. The sampling strategy is known
to bias the prevalence of conditions and ideally, prevalence studies recruit a (non-probabilistic)
consecutive sample because they are more likely to represent the target population. In compar-
ison, convenience sampling (i.e. those with available data) and purposive sampling (e.g. reports
of individuals with specific clinical features) which are common in the included studies, intro-
duce selection bias and tend to upwardly bias estimates of symptom prevalence. Equally,
enrolling patients from hospital settings rather than the community is more likely to upwardly
bias the estimates of prevalence. Overall, we suspect that our results over-estimate the true
prevalence of symptoms amongst test-positive adults.
In some instances, it was impossible to ascertain whether different publications which origi-
nated from the same hospital or region included (some of) the same subjects because the
recruitment timeframes and sampling strategies were not sufficiently described in the study
methods. We recommend that future publications detail (where possible) if their sample is
also represented in other works and describe their methods in accordance with relevant
reporting guidelines.
The way in which we extracted some of the data might bias the findings. We dichotomised
fever (based on the definition in the parent study) and thresholds differed study-to-study
(between 37˚C and 38˚C, S2 Table) which limits the transferability of the findings to clinical
practice. We also did not extract data on combinations of symptoms (such as fever and cough
together, or diarrhoea and vomiting for example) which was on oversight in the protocol
development phase though equally, this was poorly reported in the literature. Future research-
ers who wish to build upon this dataset might consider extracting combinations of symptoms
alongside isolated symptoms from the few studies were this is reported [174].
Conclusions
We confirm that fever and cough remain the most prevalent symptoms of adults infected by
SARS-CoV-2. However, there is a large proportion of infected adults which symptoms-alone
do not identify. To expedite future iterations of this work, our data is freely available in the
Open Science Framework repository.
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